


09-28-05

#1647  
FW

PTO/SB/21 (09-04)



# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

10

Application Number

09/322,289

Filing Date

May 28, 1999

First Named Inventor

Schenk, Dale B.

Art Unit

1647

Examiner Name

Sharon L. Turner

Attorney Docket Number

15270J-004740US

## ENCLOSURES (Check all that apply)

- |  |  |   |
|--|--|---|
| <input checked="" type="checkbox"/> Fee Transmittal Form<br><input type="checkbox"/> Fee Attached<br><input type="checkbox"/> Amendment/Reply<br><input type="checkbox"/> After Final<br><input type="checkbox"/> Affidavits/declaration(s)<br><input type="checkbox"/> Extension of Time Request<br><input type="checkbox"/> Express Abandonment Request<br><input checked="" type="checkbox"/> Supplemental Information<br>Disclosure Statement (6 pgs.) PTO/SB/08A<br>(1 pg.) PTO/SB/08B (1 pgs.); * copies of<br>cited references 627-637.<br><input type="checkbox"/> Certified Copy of Priority<br>Document(s)<br><input type="checkbox"/> Reply to Missing Parts/ Incomplete<br>Application<br><input type="checkbox"/> Reply to Missing Parts<br>under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)<br><input type="checkbox"/> Licensing-related Papers<br><input type="checkbox"/> Petition<br><input type="checkbox"/> Petition to Convert to a<br>Provisional Application<br><input type="checkbox"/> Power of Attorney, Revocation<br>Change of Correspondence Address<br><input type="checkbox"/> Terminal Disclaimer<br><input type="checkbox"/> Request for Refund<br><input type="checkbox"/> CD, Number of CD(s) _____<br><input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance Communication to TC<br><input type="checkbox"/> Appeal Communication to Board<br>of Appeals and Interferences<br><input type="checkbox"/> Appeal Communication to TC<br>(Appeal Notice, Brief, Reply Brief)<br><input type="checkbox"/> Proprietary Information<br><input type="checkbox"/> Status Letter<br><input checked="" type="checkbox"/> Other Enclosure(s) (please identify<br>below):<br>Return postcard |
|--|--|---|

Remarks

The Commissioner is authorized to charge any additional fees to Deposit  
Account 20-1430.

\* Not included in "Total Number of Pages In This Submission"

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name

Townsend and Townsend and Crew LLP

Signature

Printed name

Joe Liebeschuetz

Date

September 26, 2005

Reg. No.

37,505

## CERTIFICATE OF TRANSMISSION/MAILING

Express Mail Label: EV 656 871 866 US

I hereby certify that this correspondence is being deposited with the United States Postal Service with "Express Mail Post Office to Address" service under 37 CFR 1.10 on this date September 26, 2005 and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.


Signature

Typed or printed name

William Carr

Date

September 26, 2005



Effective on 12/29/2004.  
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

# FEE TRANSMITTAL

## For FY 2005

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$180.00)

### Complete if Known

Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Schenk
Examiner Name	Turner, S. L.
Art Unit	1647
Attorney Docket No.	15270J-004740US

### METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): \_\_\_\_\_

☒ Deposit Account Deposit Account Number: 20-1430 Deposit Account Name: Townsend and Townsend and Crew LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee

☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038

### FEE CALCULATION

#### 1. BASIC FILING, SEARCH, AND EXAMINATION FEES

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Small Entity	Fee (\$)	Small Entity	Fee (\$)	Small Entity	Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

#### 2. EXCESS CLAIM FEES

Fee Description	Small Entity	
	Fee (\$)	Fee (\$)
Each claim over 20 or, for Reissues, each claim over 20 and more than in the original patent	50	25
Each independent claim over 3 or, for Reissues, each independent claim more than in the original patent	200	100
Multiple dependent claims	360	180

Total Claims      Extra Claims      Fee (\$)      Fee Paid (\$)      Multiple Dependent Claims

\_\_\_\_\_ - 20 or HP = \_\_\_\_\_ x \_\_\_\_\_ \$ = \_\_\_\_\_ Fee (\$)      Fee Paid (\$)

HP = highest number of total claims paid for, if greater than 20

Indep. Claims      Extra Claims      Fee (\$)      Fee Paid (\$)

\_\_\_\_\_ - 3 or HP = \_\_\_\_\_ x \_\_\_\_\_ \$ = \_\_\_\_\_

HP = highest number of independent claims paid for, if greater than 3

#### 3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets      Extra Sheets      Number of each additional 50 or fraction thereof      Fee (\$)      Fee Paid (\$)

\_\_\_\_\_ - 100 = \_\_\_\_\_ / 50 = \_\_\_\_\_ (round up to a whole number) x \_\_\_\_\_ = \_\_\_\_\_

#### 4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other: Information Disclosure Statement (after office action)

Fees Paid (\$)

180.00

#### SUBMITTED BY

Signature		Registration No. (Attorney/Agent) 37,505	Telephone (650) 326-2400
Name (Print/Type)	Joe Liebeschuetz		Date September 26, 2005

"Express Mail" Label No. EV 656 871 866 US

Date of Deposit: September 26, 2005

PATENT

Attorney Docket No.: 15270J-004740US

Client Reference No.: 209-US-CIP5

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450



*William Carr*  
William Carr

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Schenk, Dale B.

Application No.: 09/322,289

Filed: May 28, 1999

For: PREVENTION AND TREATMENT  
OF AMYLOIDOGENIC DISEASE

Examiner: Turner, Sharon L.

Art Unit: 1647

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER 37  
CFR §1.97 and §1.98

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of references 627-637 are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Applicant also cites commonly owned copending applications directed to related subject matter:

09/29/2005 MAHME1 00000092 201430 09322289 09/201,430 filed 11/30/98 issued as U.S. 6,787,523 on 09/07/04;

01 FC:1806

180.00 DA

09/497,553 filed 02/03/00;  
09/724,477 filed 11/28/00 issued as U.S. 6,787,143 on 09/07/04;  
09/723,927 filed 11/28/00 issued as U.S. 6,787,138 on 09/07/04;  
09/723,762 filed 11/28/00 issued as U.S. 6,787,144 on 09/07/04;  
09/724,102 filed 11/28/00 issued as U.S. 6,787,139 on 09/07/04;  
09/724,489 filed 11/28/00 issued as U.S. 6,787,140 on 09/07/04;  
10/816,022 filed 03/31/04 issued as U.S. 6,866,850 on 03/15/05;  
10/816,529 filed 03/31/04 issued as U.S. 6,818,218 on 11/16/04;  
10/815,391 filed 03/31/04 issued as U.S. 6,866,849 on 03/15/05;  
10/934,818 filed 09/02/04;  
10/934,609 filed 09/02/04 issue fee paid 01/24/05;  
10/933,559 filed 09/02/04 issue fee paid 01/24/05;  
10/934,819 filed 09/02/04;  
10/815,353 filed 03/31/04 issued as U.S. 6,808,712 on 10/26/04;  
10/816,380 filed 03/31/04 issue fee paid 01/24/05;  
10/815,404 filed 03/31/04 issue fee paid 11/12/04;  
09/322,289 filed 05/28/99;  
09/723,713 filed 11/27/00;  
09/723,760 filed 11/27/00;  
09/724,319 filed 11/27/00;  
09/723,384 filed 11/27/00 issued as U.S. 6,710,226 on 03/23/04;  
09/724,495 filed 11/27/00;  
10/788,666 filed 02/27/04;  
10/429,216 filed 05/30/03;  
10/828,548 filed 04/19/04;  
10/923,471 filed 08/20/04;  
10/923,474 filed 08/20/04;  
10/928,926 filed 08/27/04;  
10/923,605 filed 08/20/04;  
10/923,267 filed 08/20/04;

10/923,469 filed 08/20/04;  
09/580,015 filed 05/26/00;  
09/724,940 filed 11/28/00 issue fee paid 11/12/04;  
09/724,961 filed 11/28/00 issued as U.S. 6,743,427 on 06/01/04;  
09/580,018 filed 05/26/00 issued as U.S. 6,761,888 on 07/13/04;  
09/724,552 filed 11/28/00 issued as U.S. 6,750,324 on 06/15/04;  
09/723,544 filed 11/28/00;  
09/724,273 filed 11/28/00;  
09/724,551 filed 11/28/00 issued as U.S. 6,787,637 on 09/07/04;  
09/724,288 filed 11/28/00;  
10/777,792 filed 02/11/04;  
10/890,024 filed 04/12/04;  
10/889,999 filed 04/12/04;  
10/890,000 filed 07/12/04;  
10/890,070 filed 07/12/04;  
10/890,071 filed 07/12/04;  
09/580,019 filed 05/26/00;  
09/723,765 filed 11/28/00;  
09/724,291 filed 11/28/00;  
10/822,968 filed 04/12/04;  
09/724,929 filed 11/28/00;  
09/724,567 filed 11/28/00 issued as U.S. 6,890,535 on 05/10/05;  
09/724,575 filed 11/28/00;  
09/724,953 filed 11/28/00 issued as U.S. 6,875,434 on 04/05/05;  
09/724,570 filed 11/28/00 issue fee paid 02/10/05;  
09/585,656 filed 06/01/00;  
09/723,766 filed 11/27/00;  
09/723,725 filed 11/27/00;  
09/579,690 filed 05/26/00;  
09/979,701 filed 03/13/01 (U.S. Nat'l Stage of PCT/US00/14810 filed 05/26/00);

09/979,952 filed 04/09/02 (U.S. Nat'l Stage of PCT/US00/15239 filed 06/01/00);  
issued as U.S. 6,913,745 on 07/05/05; and,

09/980,568 filed 03/12/02 (U.S. Nat'l Stage of PCT/US00/15302 filed 06/01/00).

Applicant also cites the following copending applications directed to related  
subject matter but subject to different assignment:

10/010,942 filed 12/06/01;  
10/789,273 filed 02/27/04;  
10/232,030 filed 08/30/02;  
10/010,942 filed 12/06/01;  
10/388,389 filed 03/12/03;  
10/703,713 filed 11/07/03;  
10/704,070 filed 11/07/03;  
10/388,214 filed 03/12/03;  
10/858,855 filed 06/01/04;  
10/771,174 filed 02/04/04.  
60/622,525 filed 10/26/04;  
60/636,684 filed 12/15/04;  
60/636,842 filed 12/15/04;  
60/637,253 filed 12/16/04;  
60/636,810 filed 12/15/04;  
60/637,138 filed 12/16/04;  
60/636,776 filed 12/15/04;  
60/636,687 filed 12/15/04.

Applicant further cites the following commonly owned abandoned applications  
directed to related subject matter:

60/067,740 filed 12/02/97;  
60/080,970 filed 04/07/98;  
60/067,219 filed 12/03/97;  
60/079,697 filed 03/27/98;

09/204,838 filed 12/03/98;  
09/724,921 filed 11/28/00;  
09/724,929 filed 11/28/00;  
60/137,010 filed 06/01/99;  
60/251,892 filed 12/06/00;  
60/137,047 filed 06/01/99;  
60/136,655 filed 05/28/99; and  
09/723,544 filed 11/28/00.

Applicant also cites the following abandoned application directed to related subject matter but subject to different assignment:

60/251,892 filed 12/06/00;  
60/474,654 filed 05/30/03;  
60/530,481 filed 12/17/03;  
60/444,150 filed 02/01/03; and,  
60/363,751 filed 03/12/02.

Applicant points out that the following applications are now commonly assigned but were previously subject to different assignment than the present application:


60/067,219 filed 12/03/97;  
60/079,697 filed 03/27/98;  
09/204,838 filed 12/03/98;  
09/724,921 filed 11/28/00; and,  
09/724,929 filed 11/28/00.

Applicant understands the Examiner can access papers from the prosecution of the cited cases electronically via PALM. However, if the Examiner has difficulty obtaining papers from that source he or she is invited to call the undersigned who will be happy to supply them.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance. Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Joe Liebeschuetz  
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 650-326-2400  
Fax: 650-326-2422  
JOL:crf



# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**Complete if Known**

Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Schenk, Dale B.
Art Unit	1647
Examiner Name	Turner, Sharon L.
Attorney Docket Number	15270J-004740US

Sheet	1	of	2
-------	---	----	---

[illegible][illegible]Date  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

2

**Complete if Known**

Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Schenk, Dale B.
Art Unit	1647
Examiner Name	Turner, Sharon L.
Attorney Docket Number	15270J-004740US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	634	Genbank Accession number AAB48800, "Anti-DNA immunoglobulin light chain IgG [Mus musculus]," 09/14/01.	
	635	Genbank Accession number CAA46659, "IgE antibody light chain(VJ)," 06/15/93.	
	636	Genbank Accession number X65775.1, "M.musculus DNA for IgE antibody light chain (VJ)," 06/15/93.	
	637	Genbank Accession number AAD26773, "Immunoglobulin heavy chain VH3609-JH3 region [Mus musculus]," 04/22/99.	
	628	KOFLER et al., "Mechanism of Allergic Cross-Reactions--III. cDNA Cloning and Variable-Region Sequence Analysis of Two IgE Antibodies Specific for Trinitrophenyl," <u>Mol. Immunology</u> , 29(2):161-166 (1992).	
	627	KRISHNAN et al., "Correlation Between the Amino Acid Position of Arginine in VH-CDR3 and Specificity for Native DNA Among Autoimmune Antibodies <sup>1,2</sup> ," <u>J. Immunol.</u> , 157(6):2430-2439 (1996).	
	629	SEIDL et al., "Predominant V <sub>H</sub> genes expressed in innate antibodies are associated with distinctive antigen-binding sites," <u>PNAS</u> , 96:2262-2267 (1999).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.